TCR2 Therapeutics, Inc. logo

TCRR

TCR2 Therapeutics, Inc.

$1.33

Earnings Summary

Net Profits
$-30.59Mn

Highlights

Net Profits:

TCR2 Therapeutics, Inc.’s net profit fell -16.58% since last year same period to $-30.59Mn in the Q3 2022. On a quarterly growth basis, TCR2 Therapeutics, Inc. has generated 3.19% jump in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the TCR2 Therapeutics, Inc. post its latest quarter earnings

EPS Estimate Current Year
-0.8

Highlights

EPS Estimate Current Year:

TCR2 Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.8.

Key Ratios

Key ratios of the TCR2 Therapeutics, Inc. post its Q2 2022 earnings

Earning Per Share (EPS)
-0.82
Return on Assets (ROA)
-0.23
Return on Equity (ROE)
-0.47

Highlights

Earning Per Share (EPS):

TCR2 Therapeutics, Inc.’s earning per share (EPS) fell -28.12% since last year same period to -0.82 in the Q2 2022. This indicates that the TCR2 Therapeutics, Inc. has generated -28.12% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. TCR2 Therapeutics, Inc.’s return on assets (ROA) stands at -0.23.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. TCR2 Therapeutics, Inc.’s return on equity (ROE) stands at -0.47.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2021-08-05
-0.58
-0.64
-9.63%
2022-03-22
-0.73
-0.72
1.37%
2021-11-10
-0.63
-0.69
-9.33%
2021-05-13
-0.53
-0.58
-8.53%

Company Information

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).

Organisation
TCR2 Therapeutics, Inc.
Headquarters
100 Binney Street, Cambridge, MA, United States, 02142
Employees
105
Industry
Pharmaceuticals: Major
CEO
Garry Menzel

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*